{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:41:38Z","timestamp":1792633298900,"version":"4.5.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review summarizes the recent developments about anti-MDA5 antibody positive dermatomyositis with a focus on its pathogenesis, clinical features and treatment options of rapidly progressive interstitial lung disease, its most ominous complication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Anti-MDA5+ dermatomyositis has a heterogeneous clinical spectrum with different patient subsets exhibiting widely different outcomes; severe acute interstitial lung disease is the main factor impacting prognosis. The pathogenetic role of anti-MDA5 antibodies is an active area of investigation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Anti-MDA5+ dermatomyositis has a wider spectrum of manifestations than previously thought. A high index of suspicion is needed not to miss atypical presentations. In the setting of acute interstitial lung involvement, once a confident diagnosis is made, an aggressive approach with early combined immunosuppression affords the best chances of survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000908","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T14:38:14Z","timestamp":1662993494000},"page":"365-373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":33,"title":["Anti-MDA5 dermatomyositis: an update from bench to bedside"],"prefix":"10.1097","volume":"34","author":[{"given":"Enrico","family":"Fuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Zanatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ghirardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/BOR.0000000000000831","article-title":"Lymphocyte immunophenotyping in inflammatory myositis: a review","volume":"33","author":"Franco","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multicenter study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Myositis Genetics Consortium. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00296-018-3991-7","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review","volume":"38","author":"Gonz\u00e1lez-Moreno","year":"2018","journal-title":"Rheumatol Int"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","article-title":"Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry","volume":"41","author":"Mehta","year":"2021","journal-title":"Rheumatol Int"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"747116","DOI":"10.3389\/fimmu.2021.747116","article-title":"COVID-19 disease and dermatomyositis: a mini-review","volume":"12","author":"Qian","year":"2022","journal-title":"Front Immunol"},{"key":"R10-20250526","article-title":"Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future","author":"Wang","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"2001618","DOI":"10.1183\/13993003.01618-2020","article-title":"Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?","volume":"56","author":"Giannini","year":"2020","journal-title":"Eur Respir J"},{"key":"R12-20250526","first-page":"1","article-title":"The type I interferonopathies: 10\u200ayears on","volume":"20","author":"Crow","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.40179","article-title":"Musculoskeletal disease in MDA5-related type I interferonopathy: a Mendelian mimic of Jaccoud's arthropathy","volume":"69","author":"de Carvalho","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"238-242","DOI":"10.1038\/s41586-018-0363-0","article-title":"Mitochondrial double-stranded RNA triggers antiviral signalling in humans","volume":"560","author":"Dhir","year":"2018","journal-title":"Nature"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"19409","DOI":"10.1074\/jbc.M112.353557","article-title":"Neutrophils express distinct RNA receptors in a noncanonical way","volume":"287","author":"Berger","year":"2012","journal-title":"J Biol Chem"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/rheumatology\/keab268","article-title":"Distribution of antimelanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5+ dermatomyositis","volume":"61","author":"Chen","year":"2021","journal-title":"Rheumatology"},{"key":"R18-20250526","first-page":"keac229","article-title":"Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease","author":"Xu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated Gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.cell.2021.08.016","article-title":"The interferon landscape along the respiratory tract impacts the severity of COVID-19","volume":"184","author":"Sposito","year":"2021","journal-title":"Cell"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41577-020-00429-3","article-title":"The type I interferon response in COVID-19: implications for treatment","volume":"20","author":"Lee","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R23-20250526","first-page":"903","article-title":"Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymyositis and dermatomyositis","volume":"33","author":"Funauchi","year":"2006","journal-title":"J Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"151","DOI":"10.55563\/clinexprheumatol\/ubov8b","article-title":"Evaluation of biomarkers related to endothelial dysfunction: proof of vasculopathy in antimelanoma differentiation-associated gene 5 dermatomyositis","volume":"39","author":"He","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatology"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/key425","article-title":"CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"791348","DOI":"10.3389\/fimmu.2021.791348","article-title":"Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03009740802687455","article-title":"Association of distinct clinical subsets with myositis-specific autoantibodies towards anti155\/140-kDa polypeptides, anti140-kDa polypeptides, and antiaminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study","volume":"38","author":"Fujikawa","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Antimelanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"290797","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res"},{"key":"R32-20250526","first-page":"891","article-title":"Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis","volume":"32","author":"Ceribelli","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of antimelanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"102788","DOI":"10.1016\/j.autrev.2021.102788","article-title":"The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger","volume":"20","author":"Toquet","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"304","DOI":"10.55563\/clinexprheumatol\/df2oc3","article-title":"Antimelanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses","volume":"40","author":"Yang","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"802753","DOI":"10.3389\/fmed.2021.802753","article-title":"Spontaneous intramuscular hemorrhage in anti-MDA5 positive dermatomyositis: a case series and literature review","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"20406223221098128","DOI":"10.1177\/20406223221098128","article-title":"Antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome","volume":"13","author":"Ding","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/03009742.2019.1653493","article-title":"Three cases of autoimmune-associated haemophagocytic syndrome in dermatomyositis with anti-MDA5 autoantibody","volume":"49","author":"Honda","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2021-eular.3401","article-title":"POS0879 clinical features, prognostic factors, and outcome of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease: a multicenter study of 238 patients","volume":"80","author":"Xu","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14397595.2020.1740400","article-title":"Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age","volume":"31","author":"Yamaguchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"845988","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"860798","DOI":"10.3389\/fmed.2022.860798","article-title":"A matrix prediction model for the 6-month mortality risk in patients with anti-melanoma differentiation-associated protein-5-positive dermatomyositis","volume":"9","author":"Ouyang","year":"2022","journal-title":"Front Med"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/cancers13030539","article-title":"Systematic review and metanalysis of oncomarkers in IPF patients and serial changes of oncomarkers in a prospective Italian real-life case series","volume":"13","author":"d\u2019Alessandro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.mayocp.2018.09.002","article-title":"Interstitial lung disease and other pulmonary manifestations in connective tissue diseases","volume":"94","author":"Mira-Avendano","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2169\/internalmedicine.55.5774","article-title":"Radiological and pathological correlation in anti-MDA5 antibody-positive interstitial lung disease: rapidly progressive perilobular opacities and diffuse alveolar damage","volume":"55","author":"Chino","year":"2016","journal-title":"Intern Med"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.chest.2020.10.096","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: perhaps some potential details to consider","volume":"159","author":"Wang","year":"2021","journal-title":"Chest"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"17070","DOI":"10.1038\/s41598-021-96292-w","article-title":"A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis","volume":"11","author":"Xu","year":"2021","journal-title":"Sci Rep"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10067-021-06033-7","article-title":"Quantitative CT analysis of interstitial pneumonia in antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study","volume":"41","author":"Yamaguchi","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of antimelanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"151959","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1684\/ejd.2019.3634","article-title":"Clinical features and poor prognostic factors of antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease","volume":"29","author":"Motegi","year":"2019","journal-title":"Eur J Dermatol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/medicina57040347","article-title":"Management of myositis-associated interstitial lung disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Antimelanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"105983","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD","volume":"172","author":"Mao","year":"2020","journal-title":"Respir Med"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12890-017-0479-2","article-title":"Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias","volume":"17","author":"Okabayashi","year":"2017","journal-title":"BMC Pulm Med"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"2102968","DOI":"10.1183\/13993003.02968-2021","article-title":"Extracorporeal life support allows lung transplant in anti-MDA5+ rapidly progressive interstitial lung disease","volume":"59","author":"Bay","year":"2022","journal-title":"Eur Respir J"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/medicina57121358","article-title":"Combination therapy with rituximab, tofacitinib and pirfenidone in a patient with rapid progressive interstitial lung disease (RP-ILD) due to MDA5 antibody-associated dermatomyositis: a case report","volume":"57","author":"Yen","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R65-20250526","first-page":"keac030","article-title":"Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients","volume":"20","author":"Hensgens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R66-20250526","first-page":"keac094","article-title":"Predictors of rapidly progressive- interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis","volume":"14","author":"So","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/IJGM.S327751","article-title":"Evaluation of prognostic factors in anti-MDA5 antibody-positive patients in Chongqing, China: a retrospective study","volume":"14","author":"Zhou","year":"2021","journal-title":"Int J Gen Med"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR Model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:19:20Z","timestamp":1748294360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000908","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]}}}